Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity assays for antibody–drug conjugates: case study with ado-trastuzumab emtansine
Authors
Keywords
-
Journal
Bioanalysis
Volume 5, Issue 9, Pages 1007-1023
Publisher
Future Science, LTD
Online
2013-05-03
DOI
10.4155/bio.13.64
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics
- (2013) Surinder Kaur et al. Bioanalysis
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody–drug conjugate therapeutic
- (2012) Montserrat Carrasco-Triguero et al. Bioanalysis
- The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies
- (2012) Sara A. Hurvitz et al. Therapeutic Advances in Medical Oncology
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer
- (2011) Jacob Mathew et al. CURRENT OPINION IN ONCOLOGY
- Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
- (2011) Howard A Burris EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunogenicity of Therapeutic Proteins: The Use of Animal Models
- (2011) Vera Brinks et al. PHARMACEUTICAL RESEARCH
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel homogeneous Biotin–digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum
- (2010) Zhihua Julia Qiu et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Clinical immunogenicity specificity assessments: A platform evaluation
- (2010) Kun Peng et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Rationale and development of multispecific antibody drugs
- (2010) Jijie Gu et al. Expert Review of Clinical Pharmacology
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
- (2008) Eugen Koren et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
- (2008) Gopi Shankar et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now